Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Core Insights - Invivyd, Inc. has appointed Kristie Kuhl as Chief Communications Officer to enhance its communications and patient advocacy efforts as the company focuses on providing monoclonal antibodies for viral disease prevention and treatment [1][3] Company Overview - Invivyd, Inc. is a biopharmaceutical company dedicated to delivering protection against serious viral infectious diseases, starting with SARS-CoV-2 [4] - The company utilizes a proprietary integrated technology platform designed to assess, monitor, develop, and adapt to create best-in-class antibodies [4] - In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody in its pipeline [4] Leadership and Expertise - Kristie Kuhl brings extensive experience in healthcare and pharmaceutical communications, previously serving as Global Managing Director, Health & Wellness at Zeno Group [2] - Kuhl has been recognized as a significant influencer in health communications, including being named in PRWeek's 2024 Health Influencer 30 [2] - The Chairman of the Invivyd Board of Directors emphasized the importance of Kuhl's experience in building high-impact healthcare narratives and fostering trust with stakeholders [3]